Skip to main content

Table 1 The approved CAR-T products for B-cell non-Hodgkin lymphoma

From: Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

Product CAR construct Year of approval Indication Bridging therapy CAR-T dose ORR CR rate Median PFS Incidence of grade 3/4 CRS Incidence of grade3/4 ICANS
Axicabtagene ciloleucel CD19-CD28-CD3ζ 2017 Refractory LBCL No 2 × 10^6 cell/kg 83% 58% 5.9 months (3.3 to 15.0) 11% (12/108) 32%
Tisagenlecleucel CD19–4-1BB - CD3ζ 2018 Relapsed or refractory DLBCL in adults Yes (0.1–6) × 10^8 CAR-positive viable T cells 52% 40% 8.3 months (5.8 to 11.7) 22% 12%
Brexucabtagene autoleucel CD19-CD28-CD3ζ 2020 Relapsed or refractory MCL Yes 2 × 10^6 cell/kg 85% 59% 4.8 months 15% 31%
Breyanzi (Lisocabtagene maraleucel) CD19–4-1BB - CD3ζ 2021 Relapsed or refractory LBCL Yes 50 × 106, 100 × 106 and 150 × 106 CAR-positive T cells 73% 53% NR 2% (6/269) 10% (27/269)
  1. Abbreviations: ORR objective response rate, CR complete response, PFS progression-free survival, CRS cytokine release syndrome, ICANS immune effector cell-associated neurotoxicity syndrome, LBCL large B-cell lymphoma, DLBCL diffuse large B-celllymphoma, MCL mantle-cell lymphoma